Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Locally advanced unresectable pancreatic ductal adenocarcinoma, drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No local therapy after chemotherapy has lengthened survival in a randomised trial apart from tumour treating fields.
Conversion surgery is uncommon and its benefit over continued non-surgical treatment is unproven.
CT cannot distinguish fibrosis from living tumour after induction, so restaging is unreliable.
Cachexia, pain and biliary complications limit how much treatment patients can receive.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Optune Pax, locally advanced pancreatic cancer with chemotherapy (PANOVA-3)
Locally advanced pancreatic cancer with chemotherapy
OS 13.
A milestone in how this cancer is treated.
OS 16.